Novartis’ Beovu secures FDA approval for wet AMD treatment

This article was originally published here

Beovu, which is also known as RTH258, is now the first anti-VEGF to be approved by the regulator. According to Novartis, the drug can offer greater fluid resolution

The post Novartis’ Beovu secures FDA approval for wet AMD treatment appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply